InvestorsHub Logo
Followers 15
Posts 673
Boards Moderated 0
Alias Born 02/10/2010

Re: None

Saturday, 11/22/2014 7:58:18 PM

Saturday, November 22, 2014 7:58:18 PM

Post# of 639
Check this out. So in 2013 Merck (who is in talks now with Newlink to help with production of VSV-EBOV) actually spun off and sold their vaccine division to GSK (which included GSK's current Ebola vaccine)

There was an article last week that said GSK and NewLink may actually join forces, apparently their vacines actually compliment one another for effectivness.

Really all speculation on my part, love to read between the lines with DD. Link below is from 2013 where Merck sold off the division.

http://www.startupticker.ch/en/news/may-2013/gsk-acquires-okairos-ag-for-eur-250-mio#.VHEvllDIa7k

Under the terms of the transaction, GSK will take full ownership of the company and thus assume ownership of early stage assets for diseases such as respiratory syncytial virus (RSV), hepatitis C virus (HCV), malaria, tuberculosis, ebola and HIV, supplementing the company’s existing vaccines pipeline. GSK and the Okairos management team are committed to an innovative collaboration and will work together over the next few months to develop ways of working that will maintain the autonomy, spirit and agility of this unique small biotech firm which will be strengthened by the support and advantages that GSK can provide.